Clinical Experience with New Antiepileptic Drugs: Antiepileptic Drugs in Europe

Loiseau, P

doi:10.1111/j.1528-1157.1999.tb00925.x

Cited by 14 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On September 26, 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) and the European Medicines Agency (EMA) held their first public hearing about safety concerns with the use of medications containing sodium valproate during pregnancy [29]. Patients and carers participated in the public hearing, and both mothers and affected children expressed concern about the lack of effective risk minimization communication for safety of valproate during pregnancy, despite the drug having been authorized for more than 50 years [30]. After the public hearing, the PRAC and the EMA provided new measures for comprehensive risk minimization, including the following [29]:…”

Section: Discussionmentioning

confidence: 99%

Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content Analysis

Rezaallah¹,

Lewis²,

Pierce³

et al. 2019

J Med Internet Res

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) is a chronic neurological disease occurring mostly in women of childbearing age. Pregnant women with MS are usually excluded from clinical trials; as users of the internet, however, they are actively engaged in threads and forums on social media. Social media provides the potential to explore real-world patient experiences and concerns about the use of medicinal products during pregnancy and breastfeeding. Objective This study aimed to analyze the content of posts concerning pregnancy and use of medicines in online forums; thus, the study aimed to gain a thorough understanding of patients’ experiences with MS medication. Methods Using the names of medicinal products as search terms, we collected posts from 21 publicly available pregnancy forums, which were accessed between March 2015 and March 2018. After the identification of relevant posts, we analyzed the content of each post using a content analysis technique and categorized the main topics that users discussed most frequently. Results We identified 6 main topics in 70 social media posts. These topics were as follows: (1) expressing personal experiences with MS medication use during the reproductive period (55/70, 80%), (2) seeking and sharing advice about the use of medicines (52/70, 74%), (3) progression of MS during and after pregnancy (35/70, 50%), (4) discussing concerns about MS medications during the reproductive period (35/70, 50%), (5) querying the possibility of breastfeeding while taking MS medications (30/70, 42%), and (6) commenting on communications with physicians (26/70, 37%). Conclusions Overall, many pregnant women or women considering pregnancy shared profound uncertainties and specific concerns about taking medicines during the reproductive period. There is a significant need to provide advice and guidance to MS patients concerning the use of medicines in pregnancy and postpartum as well as during breastfeeding. Advice must be tailored to the circumstances of each patient and, of course, to the individual medicine. Information must be provided by a trusted source with relevant expertise and made publicly available.

show abstract

Section: Discussionmentioning

confidence: 99%

Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content Analysis

Rezaallah¹,

Lewis²,

Pierce³

et al. 2019

J Med Internet Res

View full text Add to dashboard Cite

show abstract

“…208 Depakene ® (Valproate semi sodium) Valproate showed full potential in the treatment and prevention of scissors. 209 This is presently sold in 3 forms. Valproate: Valproic acid (free acid, trade name Depakote ® ), sodium valproate (salt, trade name Epilim ® ) and semisodium Valproate (co-crystal, trade name Depakene ® ).…”

Section: Commercial Co-crystal Formulationsmentioning

confidence: 99%

Insight into Concept and Progress on Pharmaceutical Co-Crystals: An overview

Vemuri¹,

Srinivas²

2019

IJPER

View full text Add to dashboard Cite

Pharmaceutical co-crystals have conferred significant recognition in recent past as a new solid form by virtue their capability to modulate physicochemical properties of Active Pharmaceutical Ingredient (API). Nevertheless, pharmaceutical progress of cocrystals could be provocation, the requirement for high-throughput screening methods and the techniques capable of co-crystal production in industrial scale still hamper the co-crystal used by industries. In this review, well ordered overview of pharmaceutical co-crystal is provided, with focus on role of supramolecular chemistry, co-crystal design strategies, preparation methods, physicochemical property studies, mechanism of solubility enhancement, evaluation techniques. In the present commentary, the impact of choosing appropriate process design and formulation on translational challenges has been discussed. Eventually, a short outline of applications and marketed drug products of pharmaceutical co-crystal drug substance is also described.

show abstract

“…In 1967, valproate came up as a new promising antiepileptic drug. Valproate was initially synthesized in 1881 by Beverly Burton in the USA and was initially employed as an organic solvent [41]. Newer AED such as vigabatrin (1989), lamotrigine (1990), oxcarbazepine (1990), gabapentin (1993), felbamate (1993), topiramate (1995), tiagabine (1998), zonisamide (1989 in Japan and 2000 in the USA), levetiracetam (2000), stiripentol (2002), pregabalin (2004), rufinamide (2004), lacosamide (2008), eslicarbazepine (2009), and perampanel (2012) were included in the list of medicines to be prescribed [42].…”

Section: Twentieth Centurymentioning

confidence: 99%